Q: Hello 5i team,
Valeant and Pershing Square have made a hostile bid for Allergan. Both the buyer's and the seller's prices are up this morning. But isn't it as likely that Valeant/Pershing-Square will need to sweeten their offer - in which case, why is Valeant up? I had thought that, in general, acquirers' near-term valuations went down (in anticipation of the depletion of treasury and/or dilution of equity.)
Valeant and Pershing Square have made a hostile bid for Allergan. Both the buyer's and the seller's prices are up this morning. But isn't it as likely that Valeant/Pershing-Square will need to sweeten their offer - in which case, why is Valeant up? I had thought that, in general, acquirers' near-term valuations went down (in anticipation of the depletion of treasury and/or dilution of equity.)